

Maciej Machaczka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1298311/publications.pdf>

Version: 2024-02-01

150
papers

2,907
citations

236612

25
h-index

205818

48
g-index

154
all docs

154
docs citations

154
times ranked

4274
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557. | 0.8 | 294 |
| 2 | Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2003, 31, 481-486. | 1.3 | 247 |
| 3 | Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. <i>Leukemia and Lymphoma</i> , 2011, 52, 613-619. | 0.6 | 137 |
| 4 | Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118. | 5.1 | 136 |
| 5 | Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1688-1697. | 2.0 | 131 |
| 6 | Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent <i>CARD11</i> mutations. <i>Oncotarget</i> , 2016, 7, 38180-38190. | 0.8 | 130 |
| 7 | Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. <i>Blood</i> , 2013, 121, 1345-1356. | 0.6 | 122 |
| 8 | Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. , 1999, 61, 216-217. | | 102 |
| 9 | Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 203-208. | 0.6 | 82 |
| 10 | Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803. | 2.0 | 73 |
| 11 | Hemophagocytic Syndrome in Children and Adults. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2014, 62, 385-394. | 1.0 | 53 |
| 12 | Chrysin: Perspectives on Contemporary Status and Future Possibilities as Pro-Health Agent. <i>Nutrients</i> , 2021, 13, 2038. | 1.7 | 53 |
| 13 | The Graft-Versus-Myeloma Effect: Chronic Graft-Versus-Host Disease but Not Acute Graft-Versus-Host Disease Prolongs Survival in Patients with Multiple Myeloma Receiving Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1211-1216. | 2.0 | 47 |
| 14 | Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2016, 128, 645-645. | 0.6 | 46 |
| 15 | Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2047-2055. | 2.0 | 45 |
| 16 | Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen – A national multicenter study. <i>International Journal of Cardiology</i> , 2013, 168, 5212-5217. | 0.8 | 41 |
| 17 | Presenting signs and patient variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED) Delphi initiative. <i>Internal Medicine Journal</i> , 2019, 49, 578-591. | 0.5 | 39 |
| 18 | Development of classical Hodgkin's lymphoma in an adult with biallelic STXP2 mutations. <i>Haematologica</i> , 2013, 98, 760-764. | 1.7 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 552-560. | 1.3 | 35 |
| 20 | Recent Advances in Biological Activity, New Formulations and Prodrugs of Ferulic Acid. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12889. | 1.8 | 34 |
| 21 | Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation. <i>Medical Oncology</i> , 2012, 29, 1231-1236. | 1.2 | 32 |
| 22 | Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease - a histological study. <i>European Journal of Haematology</i> , 2003, 70, 273-281. | 1.1 | 30 |
| 23 | Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1391-1396. | 2.0 | 30 |
| 24 | Twice-weekly ixazomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 231-244. | 1.2 | 30 |
| 25 | Gaucher disease with foamy transformed macrophages and erythrophagocytic activity. <i>Journal of Inherited Metabolic Disease</i> , 2011, 34, 233-235. | 1.7 | 29 |
| 26 | Substrate reduction therapy with miglustat for type 1 Gaucher disease: A retrospective analysis from a single institution. <i>Uppsala Journal of Medical Sciences</i> , 2012, 117, 28-34. | 0.4 | 26 |
| 27 | Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with <scp>CLL</scp>: a retrospective analysis from the European Society for Blood and Marrow Transplantation (<scp>EBMT</scp>). <i>British Journal of Haematology</i> , 2017, 178, 521-533. | 1.2 | 26 |
| 28 | Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 35-42. | 0.6 | 25 |
| 29 | Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123. | 0.6 | 23 |
| 30 | Acquired hemophagocytic lymphohistiocytosis associated with multiple myeloma. <i>Medical Oncology</i> , 2011, 28, 539-543. | 1.2 | 21 |
| 31 | Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891. | 1.2 | 21 |
| 32 | Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 86-92. | 0.6 | 21 |
| 33 | Treatment of multiple myeloma in patients with Gaucher disease. <i>American Journal of Hematology</i> , 2009, 84, 694-696. | 2.0 | 19 |
| 34 | Treatment of Familial Hemophagocytic Lymphohistiocytosis with Third-Party Mesenchymal Stromal Cells. <i>Stem Cells and Development</i> , 2012, 21, 3147-3151. | 1.1 | 19 |
| 35 | Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up. <i>Blood</i> , 2010, 116, 3049-3049. | 0.6 | 19 |
| 36 | Comparison of general vs regional anaesthesia for BM harvesting: a retrospective study of anaesthesia-related complications. <i>Bone Marrow Transplantation</i> , 2010, 45, 53-61. | 1.3 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Alentuzumab treatment for hemophagocytic lymphohistiocytosis. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 1-1. | 12.5 | 18 |
| 38 | Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. <i>Blood</i> , 2013, 122, 535-535. | 0.6 | 18 |
| 39 | Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 275. | 1.2 | 17 |
| 40 | Atypical cytomorphology of Gaucher cells is frequently seen in bone marrow smears from untreated patients with Gaucher disease type 1. <i>Folia Histochemica Et Cytobiologica</i> , 2015, 53, 62-69. | 0.6 | 17 |
| 41 | Impact of Imiglucerase Supply Shortage on Clinical and Laboratory Parameters in Norrbottnian Patients with Gaucher Disease Type 3. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2015, 63, 65-71. | 1.0 | 16 |
| 42 | Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial. <i>Blood</i> , 2010, 116, 38-38. | 0.6 | 16 |
| 43 | A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2165-2171. | 2.0 | 15 |
| 44 | Application of infrared spectroscopy in the identification of Ewing sarcoma: A preliminary report. <i>Infrared Physics and Technology</i> , 2017, 83, 200-205. | 1.3 | 15 |
| 45 | African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92. | 2.0 | 15 |
| 46 | Liposomal amphotericin B and surgery as successful therapy for pulmonary <i>Lichtheimia corymbifera</i> zygomycosis in a pediatric patient with acute promyelocytic leukemia on antifungal prophylaxis with posaconazole. <i>Medical Oncology</i> , 2013, 30, 433. | 1.2 | 14 |
| 47 | Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. <i>Blood</i> , 2010, 116, 41-41. | 0.6 | 14 |
| 48 | Haemophagocytic syndrome associated with Hodgkin lymphoma and <i>Pneumocystis jirovecii</i> pneumonitis. <i>British Journal of Haematology</i> , 2007, 138, 672-672. | 1.2 | 13 |
| 49 | Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?. <i>Leukemia and Lymphoma</i> , 2012, 53, 1699-1705. | 0.6 | 13 |
| 50 | Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Gaucher Disease. <i>Pediatric Hematology and Oncology</i> , 2013, 30, 459-461. | 0.3 | 13 |
| 51 | Clinical characteristics, therapy response, and outcome of 51 adult patients with hematological malignancy-associated hemophagocytic lymphohistiocytosis: a single institution experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 1840-1850. | 0.6 | 13 |
| 52 | Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. <i>Leukemia and Lymphoma</i> , 2019, 60, 471-476. | 0.6 | 13 |
| 53 | Multiple Myeloma in Pregnancy – A Review of the Literature and a Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e39-e45. | 0.2 | 12 |
| 54 | Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia – A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 667-675.e2. | 0.2 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 1828. | 1.0 | 12 |
| 56 | MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 1969-1969. | 0.6 | 12 |
| 57 | A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , 2015, 126, 3036-3036. | 0.6 | 12 |
| 58 | The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy. <i>Upsala Journal of Medical Sciences</i> , 2016, 121, 192-195. | 0.4 | 11 |
| 59 | A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. <i>British Journal of Haematology</i> , 2017, 176, 440-447. | 1.2 | 11 |
| 60 | A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509. | 2.0 | 11 |
| 61 | Effort bruising disclosing Gaucher disease in a 55-year-old non-Jewish woman. <i>Journal of Inherited Metabolic Disease</i> , 2009, 32, 758-761. | 1.7 | 10 |
| 62 | Hemophagocytic syndrome after allogeneic hematopoietic cell transplantation: more a graft rejection than an infectious process?. <i>European Journal of Haematology</i> , 2012, 88, 458-460. | 1.1 | 10 |
| 63 | Bone Marrow Assessment in the Diagnosis of Acquired Hemophagocytic Lymphohistiocytosis in Adults. <i>American Journal of Clinical Pathology</i> , 2015, 143, 308-309. | 0.4 | 10 |
| 64 | The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2015, 94, 109-114. | 1.1 | 10 |
| 65 | Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. <i>Leukemia and Lymphoma</i> , 2018, 59, 259-261. | 0.6 | 10 |
| 66 | The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1440-1452. | 0.4 | 10 |
| 67 | Unexpected cure from cutaneous leukocytoclastic vasculitis in a patient treated with N-butyldeoxynojirimycin (miglustat) for Gaucher disease. <i>Advances in Medical Sciences</i> , 2012, 57, 169-173. | 0.9 | 9 |
| 68 | Co hematolog powinien wiedzieć o chorobie Gauchera. <i>Acta Haematologica Polonica</i> , 2013, 44, 301-306. | 0.1 | 9 |
| 69 | Recurrent pulmonary aspergillosis and mycobacterial infection in an unsplenectomized patient with type 1 Gaucher disease. <i>Upsala Journal of Medical Sciences</i> , 2014, 119, 44-49. | 0.4 | 9 |
| 70 | New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1652. | 1.0 | 9 |
| 71 | Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. <i>Cancer</i> , 2021, 127, 1816-1826. | 2.0 | 9 |
| 72 | Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers. <i>Medical Oncology</i> , 2015, 32, 90. | 1.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 3065-3065. | 0.6 | 8 |
| 74 | Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2015, 126, 1540-1540. | 0.6 | 8 |
| 75 | TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 3052-3052. | 0.6 | 8 |
| 76 | Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 28-28. | 0.6 | 8 |
| 77 | Novel heterozygous c.798C>G and c.1040T>G mutations in the GBA1 gene are associated with a severe phenotype of Gaucher disease type 1. <i>Annals of Hematology</i> , 2014, 93, 1787-1789. | 0.8 | 7 |
| 78 | G-CSF mobilized peripheral blood stem cell collection for allogeneic transplantation in healthy donors: Analysis of factors affecting yield. <i>Journal of Clinical Apheresis</i> , 2017, 32, 384-391. | 0.7 | 7 |
| 79 | Saccadic Impairments in Patients with the Norrbottnian Form of Gaucher's Disease Type 3. <i>Frontiers in Neurology</i> , 2017, 8, 295. | 1.1 | 7 |
| 80 | The influence of various therapeutic regimens on early clinical and laboratory response and outcome of children with secondary hemophagocytic lymphohistiocytosis. <i>Archives of Medical Science</i> , 2018, 1, 138-150. | 0.4 | 7 |
| 81 | Polyneuropathy in Gaucher disease type 1 and 3 – a descriptive case series. <i>Scientific Reports</i> , 2019, 9, 15358. | 1.6 | 7 |
| 82 | Tandem Autologous Stem Cell Transplants (auto-auto) with or without Maintenance Therapy Versus Single Autologous Transplant Followed by HLA-Matched Sibling Non- Myeloablative Allogeneic Stem Cell Transplant (auto-allo) for Patients (pts) with High Risk (HR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial. <i>Blood</i> , 2010, 116, 526-526. | 0.6 | 7 |
| 83 | Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. <i>American Journal of Hematology</i> , 2018, 93, E238-E241. | 2.0 | 6 |
| 84 | Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group*. <i>Leukemia and Lymphoma</i> , 2019, 60, 341-348. | 0.6 | 6 |
| 85 | Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020, 61, 2868-2875. | 0.6 | 6 |
| 86 | Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with Tj ETQq0 0 0 rgBT /Over a case series. <i>Hematological Oncology</i> , 2017, 35, 246-251. | 0.8 | 5 |
| 87 | Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. <i>Leukemia and Lymphoma</i> , 2020, 61, 3484-3492. | 0.6 | 5 |
| 88 | Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial. <i>Blood</i> , 2010, 116, 862-862. | 0.6 | 5 |
| 89 | Early access experience with VPRIVÂ®: Recommendations for "core data"™ collection. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 47, 140-142. | 0.6 | 4 |
| 90 | A Twelve-Year Follow-Up Study on a Case of Early-Onset Parkinsonism Preceding Clinical Manifestation of Gaucher Disease. <i>JIMD Reports</i> , 2011, 3, 53-57. | 0.7 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Splenectomy as a therapeutic approach in refractory hemophagocytic lymphohistiocytosis. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 159-160. | 2.5 | 4 |
| 92 | Aberrant bone marrow vascularization patterns in untreated patients with Gaucher disease type 1. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 54-59. | 0.6 | 4 |
| 93 | First Clinicogenetic Description of Parkinson's Disease Related to <i>GBA</i> Mutation S107L. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 254-258. | 0.8 | 4 |
| 94 | Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications. <i>Journal of Clinical Oncology</i> , 2020, 38, 1367-1368. | 0.8 | 4 |
| 95 | Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients. <i>Blood</i> , 2010, 116, 1938-1938. | 0.6 | 4 |
| 96 | Eosinophilia as a presenting symptom of the metastatic lung adenocarcinoma with an unknown primary localization. <i>Open Medicine (Poland)</i> , 2011, 6, 541-544. | 0.6 | 3 |
| 97 | Hemophagocytic lymphohistiocytosis in adults. <i>Uppsala Journal of Medical Sciences</i> , 2013, 118, 201-203. | 0.4 | 3 |
| 98 | Zarys objawów klinicznych, leczenia oraz trudności w rozpoznawaniu choroby Gauchera. <i>Acta Haematologica Polonica</i> , 2015, 46, 149-157. | 0.1 | 3 |
| 99 | Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant. <i>Transplantation Proceedings</i> , 2020, 52, 2186-2192. | 0.3 | 3 |
| 100 | Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 3986-3986. | 0.6 | 3 |
| 101 | Inferior Outcomes of Patients with Quad and Penta-Refractory Multiple Myeloma (MM) Compared to Those of Patients Who Have Been Quad and Penta Exposed. <i>Blood</i> , 2021, 138, 4742-4742. | 0.6 | 3 |
| 102 | Is it possible to identify siblings by studying bone marrow under a microscope? Two unusual cases of Gaucher disease. <i>Polish Journal of Pathology</i> , 2002, 53, 87-90. | 0.1 | 3 |
| 103 | High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse. <i>Medical Oncology</i> , 2013, 30, 762. | 1.2 | 2 |
| 104 | Bone and hormonal status 10 years post-allogeneic bone marrow transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13742. | 0.8 | 2 |
| 105 | Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. <i>EJHaem</i> , 2021, 2, 375-384. | 0.4 | 2 |
| 106 | Haploidentical Allogeneic Transplantation As Salvage in Relapsed Multiple Myeloma. <i>Blood</i> , 2014, 124, 5918-5918. | 0.6 | 2 |
| 107 | Real-world outcomes with panobinostat in patients with penta- and quad-refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, e19522-e19522. | 0.8 | 2 |
| 108 | Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease. <i>JIMD Reports</i> , 2022, 63, 93-100. | 0.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia. , 2013, 123, 251-2. | | 2 |
| 110 | Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 306.e1-306.e7. | 0.6 | 2 |
| 111 | Autoimmune-Associated Hemophagocytic Syndrome/Macrophage Activation Syndrome. , 0, , . | | 1 |
| 112 | Mantle cell lymphoma successfully treated in a patient with multiple endocrine neoplasia type 2: a rare combination of two malignancies. Medical Oncology, 2012, 29, 2174-2175. | 1.2 | 1 |
| 113 | Specyfika występowania limfocytozy hemofagocytarnej w okresie wieku dorosłego. Acta Haematologica Polonica, 2013, 44, 307-313. | 0.1 | 1 |
| 114 | Wartość diagnostyczna i zastosowanie kliniczne biomarkerów oraz ferrytynemii w chorobie Gauchera. Acta Haematologica Polonica, 2014, 45, 149-154. | 0.1 | 1 |
| 115 | Rzadkie choroby makrofagów u dorosłych. Acta Haematologica Polonica, 2016, 47, 146-154. | 0.1 | 1 |
| 116 | Rituximab-associated progressive multifocal leukoencephalopathy after a single cycle of R-CHOP for T-cell/histiocyte-rich large B-cell lymphoma. Acta Haematologica Polonica, 2017, 48, 205-211. | 0.1 | 1 |
| 117 | Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. , 1999, 61, 216. | | 1 |
| 118 | Vorinostat in Combination with Lenalidomide (L) and Dexamethasone (d) in Multiple Myeloma Patients Refractory to Previous Lenalidomide-Containing Regimens: Results of a Phase IIb Trial. Blood, 2015, 126, 4264-4264. | 0.6 | 1 |
| 119 | Prognostic significance of t(11;14) expression by FISH in patients with newly diagnosed multiple myeloma in the era of novel therapies.. Journal of Clinical Oncology, 2017, 35, e19525-e19525. | 0.8 | 1 |
| 120 | Patient-reported outcomes following autologous stem cell transplantation for patients with multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e22069-e22069. | 0.8 | 1 |
| 121 | Blocking MET receptor signaling in multiple myeloma cells in vitro and in vivo. Advances in Clinical and Experimental Medicine, 2018, 27, 153-158. | 0.6 | 1 |
| 122 | Autologous stem cell transplantation in multiple myeloma patients over age 75.. Journal of Clinical Oncology, 2018, 36, 8025-8025. | 0.8 | 1 |
| 123 | Predicting outcomes in multiple myeloma: do we really need another model?. Leukemia and Lymphoma, 2011, 52, 1170-1172. | 0.6 | 0 |
| 124 | Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results. Medical Oncology, 2012, 29, 2070-2076. | 1.2 | 0 |
| 125 | Hemophagocytic lymphohistiocytosis as a possible cause of prolonged fever, splenomegaly, and cytopenia. Revista Clinica Espanola, 2014, 214, 315-317. | 0.2 | 0 |
| 126 | Extraneural relapse of medulloblastoma mimicking acute leukemia: A diagnostic challenge in adult patient. Acta Haematologica Polonica, 2017, 48, 217-219. | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Elevated serum concentrations of Î²-2-microglobulin are often found at the time of diagnosis of hemophagocytic lymphohistiocytosis in adults with lymphoid and myeloid malignancies. <i>Acta Haematologica Polonica</i> , 2017, 48, 195-201. | 0.1 | 0 |
| 128 | Choroba Gauchera – zalecenia dotyczÄ...ce rozpoznawania, leczenia i monitorowania. <i>Acta Haematologica Polonica</i> , 2017, 48, 222-261. | 0.1 | 0 |
| 129 | High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM). <i>Blood</i> , 2010, 116, 1355-1355. | 0.6 | 0 |
| 130 | A Decade of Stem Cell Transplantation in Lymphoma: Single Center Experience and Outcome of 938 Consecutive Allogeneic and Autologous Hematopoietic Stem Cell Transplants Performed At John Theurer Cancer Center. <i>Blood</i> , 2011, 118, 3086-3086. | 0.6 | 0 |
| 131 | Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8011-8011. | 0.8 | 0 |
| 132 | Intermittent Zoledronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2012, 120, 1965-1965. | 0.6 | 0 |
| 133 | Haploidentical Allogeneic Transplantation Provides Comparable Outcomes to HLA-Matched or Mismatched Unrelated Donor Grafts in Hematological Malignancies. <i>Blood</i> , 2014, 124, 1226-1226. | 0.6 | 0 |
| 134 | High Rate of Engraftment Syndrome in Elderly Patients with Multiple Myeloma Receiving Autologous Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3175-3175. | 0.6 | 0 |
| 135 | Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up. <i>Blood</i> , 2015, 126, 3174-3174. | 0.6 | 0 |
| 136 | Outcomes of Salvage Stem Cell Transplantation in Hodgkin Lymphoma in a Single Institution in the Modern Era. <i>Blood</i> , 2015, 126, 5500-5500. | 0.6 | 0 |
| 137 | High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation and Receive Salvage with Donor Lymphocyte Infusions (DLI). <i>Blood</i> , 2016, 128, 5860-5860. | 0.6 | 0 |
| 138 | Long-Term Survival and Absence of Late Relapses in Patients Who Underwent Allogeneic Stem Cell Transplantation for Advanced Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 5843-5843. | 0.6 | 0 |
| 139 | 5-Day Decitabine with Mini Fludarabine and Busulfan Yields Comparable Outcomes to Mini Flu/Bu but with Increased Incidence of Severe Acute GvHD. <i>Blood</i> , 2016, 128, 3422-3422. | 0.6 | 0 |
| 140 | Long-Term Survival Is Demonstrated in Patients with Multiple Myeloma Treated with Allogeneic Hematopoietic Stem Cell Transplantation in Both the Consolidation and Salvage Settings. <i>Blood</i> , 2016, 128, 2302-2302. | 0.6 | 0 |
| 141 | High Dose Telmisartan for Prevention of Acute Graft Vs. Host Disease. <i>Blood</i> , 2016, 128, 5783-5783. | 0.6 | 0 |
| 142 | Venous Assessment Prior to Mobilization Significantly Reduced Use of Apheresis Central Venous Catheters. <i>Blood</i> , 2016, 128, 5735-5735. | 0.6 | 0 |
| 143 | Response status as predictor of survival after autologous hematopoietic cell transplant (AHCT), without or with consolidation (with bortezomib, lenalidomide (Len) and dexamethasone) and len maintenance (AM vs. ACM) versus tandem AHCT and len maintenance (TAM) for up-front treatment of patients (pts) with multiple myeloma (MM): BMT CTN0702-stamina (NCT01109004).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8010-8010. | 0.8 | 0 |
| 144 | Autologous stem cell transplantation as a treatment modality for type 1 cryoglobulinemia in monoclonal gammopathy of renal significance.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19500-e19500. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Racial differences in abnormalities by FISH in minorities with multiple myeloma: A single-center experience.. Journal of Clinical Oncology, 2017, 35, 8044-8044. | 0.8 | 0 |
| 146 | Monoclonal Gammopathy of Ocular Significance (MGOS) - a Series of Corneal Manifestations and Treatment Outcomes. Blood, 2021, 138, 2695-2695. | 0.6 | 0 |
| 147 | Impact of Treating Facility on Overall Survival and Treatment in Multiple Myeloma (MM) Using National Cancer Database (NCDB). Blood, 2021, 138, 2996-2996. | 0.6 | 0 |
| 148 | Prospective Randomized Comparative Study of Myeloablative Fludarabine/Busulfan (Flu/Bu4) and Fludarabine/Busulfan/Total Body Irradiation (Flu/Bu4/TBI) Conditioning Regimen for Patients with Myeloid Diseases. Blood, 2020, 136, 9-9. | 0.6 | 0 |
| 149 | Oral lesions in the course of myelofibrosis successfully treated using combination therapy with thalidomide, betamethasone, and cytarabine. , 2013, 123, 189-90. | | 0 |
| 150 | Counterpoints: Do patients with multiple myeloma need maintenance treatment? No, maintenance treatment should not be used outside clinical trials. Clinical Advances in Hematology and Oncology, 2015, 13, 163, 167-9. | 0.3 | 0 |